International Alliance for Biological StandardizationPlatform Technology Webinar - February 18, 2021
Platform Technology: Is it possible to reduce vaccine development time?
An IABS webinar: Thursday, February 18, 2021 from 14 :00 – 16 :30 CET
Testimonials from J&J, Curevac and BioNtech
Round table discussion with Industry, EMA, FDA, Health Canada, PEI, WHO…
Platform Technology: what are the first experiences from different players who were allowed by the authorities to use data from other programs in a platform technology approach in order to shorten the development time.
Webinar Registration link : https://www.iabs.org/platform-technology-webinar.
IABS-EU_ZAPI Stakeholders Final Conference - February 4-5, 2021
ZAPI Stakeholders Final Conference
February 4-5, 2021
A Virtual Meeting
INFORMATION ABOUT AND REGISTRATION FOR THE MEETING HERE
In March 2015, IMI (Innovative Medicine Initiative - https://www.imi.europa.eu) launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.
“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview
Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective.
The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.
The ZAPI project benefits from the assistance and financial support of
IMI and the European Commission, and in-kind contributions from EFPIA partners.
Read more: IABS-EU_ZAPI Stakeholders Final Conference - February 4-5, 2021
Meeting rescheduled - New Date Soon
Cross learning experience human and animal vaccine licensure
based on technology platforms
A Joint CEPI / IABS-EU Workshop
Registration and information about the Meeting
MEETING RESCHEDULED
The difficult situation we are facing currently in Europe
and the uncertainties concerning the evolution
of the Covid-19 pandemic has led us to once again postpone
the CEPI / IABS-EU Workshop.
More information will be posted shortly.
Meeting rescheduled - New Date - June 8-9, 2021, Ottawa, Canada
Maintaining the quality of vaccines through the use of references standards
Current challenges and future opportunities
Due to the uncertainties concerning the evolution
of the Covid-19 pandemic, the meeting is once again rescheduled
and will now take place on
June 8-9, 2021
Registration and information about the meeting
Read more: Meeting rescheduled - New Date - June 8-9, 2021, Ottawa, Canada
Meeting rescheduled NEW DATE_September 14 - 16, 2021 - Munich, Germany
Autogenous Vaccines:
Quality of production and movement in a common market
Ludwig-Maximilians-University Munich
registration and information about the meeting
Read more: Meeting rescheduled NEW DATE_September 14 - 16, 2021 - Munich, Germany
SARS-CoV-2 CHIM Webinar - June 23, 2020
IABS Webinar
SARS-CoV-2
Controlled Human Infection Models (CHIM):
Ethics, Challenge Agent Production, and Regulatory Issues
June 23rd, 2020 : 14:00-18:00 CEST
IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.
The first IABS webinar (Wednesday May 27th,14:00-16:00 CEST) provided an insight to what was known to date about
the epidemiology worldwide, the disease from an immunology viewpoint and progress regarding the development of vaccines against the virus.
The second IABS SARS CoV-2 webinar was devoted to the use of controlled human infection models (CHIM) to accelerate development and market authorization assessment of vaccines against the virus. The webinar consisted of four brief presentations to set the stage, followed by three panel discussions on ethics, challenge agent production
and quality control issues (CMC) and regulatory issues, and provided ample time for discussion between panelists and participants.
The webinar was organized under the Chatham House Rule (https://www.chathamhouse.org): participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.
The next IABS SARS CoV-2 webinar: Friday, October 16, 2020.
SARS-CoV-2 Webinar-An Update - October 16, 2020
An Update on SARS-CoV-2
Friday, October 16, 2020
14:00-16:00 CEST
The first IABS webinar (May 27th) provided insight into what was known at that point in time about SARS-CoV-2:
the epidemiology worldwide; the disease from an immunology viewpoint and the development of vaccines against the virus.
This 3rd International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of
international stakeholders, including academia, regulators, funders and industry, with a considerable delegation
from low- and middle-income countries, to provide an update on
the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2,
six months after the previous webinar.
Although SARS-CoV-2 shows limited evolution, which is beneficial for vaccine development,
recombination of SARS-CoV-2 with another CoV has led to enhanced human-to-human transmissibility of the virus.
Read the Meeting Report
5th Cell Therapy Conference, Tokyo, Japan - February 4-5, 2020
5th IABS Cell Therapy Conference
Towards international convergence of basic technical requirements
and evaluation of human cell therapy products
Muromachi Mitsui Hall & Conference
Tokyo, Japan
Organized by: International Alliance for Biological Standardization (IABS)
With the support from: Osaka University Graduate School of Medicine
6th Statistics Workshop - November 2-5, 2020, A Virtual Meeting
6th IABS Statistics Workshop:
Approaches for Improving Statistical Partnership in CMC Development,
Manufacturing, and Regulation of Biologicals
U.S. Pharrmacopeia
Rockville, Maryland
Due to restrictions associated with the SARS-COVID-2 pandemic,
the 6th IABS Statistics Workshop was held virtually.
Read more: 6th Statistics Workshop - November 2-5, 2020, A Virtual Meeting
IABS 65th Anniversary Conference on Infectious Diseases - February 26-28, 2020
New paths for sustainable solutions to tackle global and emerging infectious threats
IABS celebrated its 65th Anniversary on February 26-28, 2020, in Lyon, France.
Read more: IABS 65th Anniversary Conference on Infectious Diseases - February 26-28, 2020
Quality Requirements for Challenge Agents - October 22, 2019
Quality Requirements for Challenge Agents
An IABS-EU Meeting
Read more: Quality Requirements for Challenge Agents - October 22, 2019
Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing - October 16-17, 2018
Workshop: Implementing Non-animal Approaches to Human and Veterinary Vaccine Testing:
Achieving Scientific and Regulatory Success for Rabies and Beyond
October 16-17, 2018
National Institutes of Health, Bethesda, Maryland
The workshop agenda as well as speaker and poster abstracts are included in the e-book. The e-book and speaker slides are posted on the web (e-book* and slides**).
SARS-CoV-2 Webinar - May 27, 2020
IABS Webinar
Update on SARS-CoV-2
May 27th, 2020 : 14:00 CEST
IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.
As science is evolving day after day, it is important for many people to have an overview of the actual knowledge at a specific moment in time.
The first IABS webinar that took place Wednesday May 27th from 14:00-16:00 CEST gave you an insight to what is known about SARS-CoV-2, the epidemiology worldwide, the disease from an immunology viewpoint and where we are today with the development of vaccines against the virus.
This webinar is the first in a series of webinars to inform our network on what is known about the virus, the disease, and how to cope with it.
The recording of the webinar is available below:
2nd Setting Specifications for Biological Products - December 2-3, 2019
2nd Setting Specifications for Biological Products: A Pathway to Harmonization
Information about the meeting here
Read more: 2nd Setting Specifications for Biological Products - December 2-3, 2019
4th Cell Therapy Conference - June 5-6, 2018
4th Cell Therapy Conference
Manufacturing and Testing of Pluripotent Stem Cells
Organized by
The International Alliance for Biological Standardization - IABS
with support from and in collaboration with the
California Institute for Regenerative Medicine - CIRM
Los Angeles, California
June 5-6, 2018
Read the Meeting Report
Objectives and Expected Outcomes
The 2018 Cell Therapy conference will identify key unresolved issues that need to be addressed for the manufacture and testing of pluripotent stem cell-based therapies and provide scientific consensus on selected aspects to inform the drafting of future national and international guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.
The overall goal of the conference is to provide the target audience with an appreciation of the importance of a well-controlled manufacturing process for cell therapies that are in development, and to highlight specific areas that should be considered during early product development in order to avoid issues in later stages. The target audience includes those individuals and organizations actively pursuing research and development of cell therapies with the intent of achieving pluripotent stem cell therapy products that meets regulatory requirements for approval, thus becoming generally available to treat patients with unmet medical needs.
We will build on previous meetings that generally addressed broader themes of cell therapy studies and manufacturing issues. In addition to reviewing information on the state-of-the-art and recently generated data, this conference ill drill down to key practical issues facing cell therapy developers and regulators to expedite the safe and efficient introduction of new treatments for important diseases where unmet medical needs exist.
More specifically, the conference is expected to provide a basis for new and/or additional guidance on regulatory expectations for developing acceptable pluripotent cell therapy products including testing requirements during manufacture. Concrete conclusions and recommendations will be important outcomes, which are expected to stimulate the field to move forward in a transparent and coordinated manner.
4th Statistical and Data Management Approaches for Biotechnology Drug Development - October 30-November 1, 2017
4th Statistical and Data Management Approaches
for Biotechnology Drug Development
Venue: USP Pharmacopeia, Rockville, Maryland
October 30 - November 1, 2017
This meeting is to bring together regulators, and scientists, or those interested in statistics from academia and industry, who have a background in statistics, to help resolve existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use statistics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability, biosimilarity exercises and stability program development will be provided by the speakers and panel members. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.
Click here to learn more about the meeting
3rd Human Challenge Trials in Vaccine Development - February 6-7, 2020
3rd Human Challenge Trials in Vaccine Development
3rd Conference on Cell Therapy Manufacturing and Testing - November 2-3, 2016
3rd IABS CONFERENCE on CELL THERAPY
MANUFACTURING AND TESTING
This meeting provided an important update on the
Regulation and Standardization of Cell Therapies
November 2-3, 2016
The Wellcome Collection
London, United Kingdom
The 2016 Cell Therapy conference will identify the key issues to be addressed for the manufacture of cell therapies and provide scientific consensus on selected aspects to inform the drafting of future guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.
It is intended that the conference output should provide core elements that will be useful in establishing international consensus on the requirements for manufacture of cell based medicines and enable progress towards a potential future WHO endorsed guidance.
folder Slides are available here
Animal Testing for Vaccines, Bangkok, Thailand - December 3-4, 2019
Animal Testing for Vaccines
Implementing Replacement, Reduction and Refinement:
Challenges and Priorities
Information about the meeting here
Read more: Animal Testing for Vaccines, Bangkok, Thailand - December 3-4, 2019
5th Statistical Approaches for CMC Development and Lifecycle Management of Biotherapeutics and Vaccines - November 26-28, 2018
5th Statistical Approaches for CMC Development and
Lifecycle Management of Biotherapeutics and Vaccines
November 26-28, 2018
Venue: US Pharmacopeia
Rockville, Maryland
Objectives
This meeting is to bring together regulators and scientists to discuss statistical approaches used to help develop and manage processes, which ensure the quality and availability of biotherapeutics and vaccines. Speakers and panel members will engage with meeting participants on challenges and solutions related to CMC development and lifecycle management of biologics. Areas of attention will include Quality by Design in process and analytical development, comparability and biosimilarity, stability study design and analysis, validation, and continuous process and analytical verification. Statistical challenges related to introduction of new technologies and Big Data will be discussed. Special emphasis will be devoted to collaboration and communication, between scientists and statisticians as well as industry and regulators. The meeting will bring experts together to discuss the issues and through roundtables attempt to reach conclusions that will add value to global public health.